Articles by Justin Heifetz
Affiris clears Phase I with Parkinson's vaccine candidate
Austria-based vaccinemaker Affiris announced that its Parkinson's disease vaccine has met its primary endpoint in a small Phase I safety trial of patients receiving two different doses of the jab.
Themis Chikungunya prophylactic hits Phase I goal
Chikungunya fever is a dangerous tropical virus that has recently surfaced in the U.S. after erupting in the Caribbean. But Austria-based Themis Bioscience may eventually have a way to combat it, new data suggest.
Inovio sells off animal health assets to zero in on vaccines
This week, the company's VGX Animal Health subsidiary sold its animal health assets--including an exclusive license with Inovio for animal DNA vaccines--to South Korea's Plumbline Life Sciences.
